UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 22, 2006
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 0-26642 | 87-0494517 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (801) 584-3600
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Page 1 of 4 pages
| ITEM 2.02 | Results of Operations and Financial Condition |
On August 22, 2006, Myriad Genetics, Inc. announced its financial results for the three and twelve months ended June 30, 2006. The earnings release is attached hereto as an exhibit to this Current Report on Form 8-K and is being furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| ITEM 8.01 | Other Events |
On August 22, 2006, Myriad Genetics, Inc. announced that it has completed enrollment in its U.S. Phase 3 clinical trial of Flurizan™ for patients with Alzheimer’s disease. The information in the press release dated August 22, 2006 is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.2 hereto.
| ITEM 9.01 | Financial Statements and Exhibits. |
(d)
| Exhibit Number |
Description | |
| 99.1 | Earnings release dated August 22, 2006 for the three and twelve months ended June 30, 2006. | |
| 99.2 | The Registrant’s press release dated August 22, 2006 concerning the completed enrollment of U.S. Phase 3 clinical trial of Flurizan. | |
Page 2 of 4 pages
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MYRIAD GENETICS, INC. | ||||||||
| Date: August 22, 2006 | By: |
/s/ Peter D. Meldrum | ||||||
| Peter D. Meldrum | ||||||||
| President and Chief Executive Officer | ||||||||
Page 3 of 4 pages
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Earnings release dated August 22, 2006 for the three and twelve months ended June 30, 2006. | |
| 99.2 | The Registrant’s press release dated August 22, 2006 concerning the completed enrollment of U.S. Phase 3 clinical trial of Flurizan. | |
Page 4 of 4 pages